Research programme: NADPH oxidase inhibitors - GenKyoTex

Drug Profile

Research programme: NADPH oxidase inhibitors - GenKyoTex

Alternative Names: GKT-03; GKT-136901; GKT-771; GKT-901; HTS programme; NOX inhibitors - GenKyoTex

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenKyoTex
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action CYBB protein inhibitors; NADPH oxidase inhibitors; NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Inflammation; Pain
  • Research Cancer; CNS disorders; Hearing loss
  • Discontinued Diabetic nephropathies; Idiopathic pulmonary fibrosis

Most Recent Events

  • 05 May 2017 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in Switzerland (unspecified route)
  • 05 May 2017 Discontinued for Diabetic nephropathies in Switzerland (unspecified route)
  • 05 May 2017 Early research in Hearing loss in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top